Myelos

Myelos is a San Diego-based biotechnology company dedicated to developing first-in-class, non-opioid treatments for chronic neuropathic pain and neurodegenerative diseases. The company's lead candidate, MYE-001, is an orally available small molecule designed to mimic the neuroprotective effects of prosaptide by targeting G-protein coupled receptors GPR37 and GPR37L1. This approach aims to promote nerve regeneration and provide symptomatic relief without the side effects associated with opioids or current standard-of-care treatments. Myelos' technology is based on foundational research from the Scripps Research Institute and has been supported by significant non-dilutive funding from the NIH. The company is currently advancing its lead program through IND-enabling studies to address high unmet needs in diabetic and chemotherapy-induced peripheral neuropathy.